Finally, Gewirtz et al., discovered that patients from a specific ethnic background with deficient TLR5 were protected from developing CD, advocating the pharmacological inhibition of the TLRs as an alternative to anti-TNF compounds to treat IBD [104]. Here, TNF is linked to inflammatory bowel disease.